Myeloid Therapeutics rebranded as Create Medicines and broadened its in‑vivo immune programming strategy beyond myeloid cells to include T and NK cells using mRNA‑LNP platforms, aiming for redosable, off‑the‑shelf immunotherapies. The company is advancing in‑body CAR and immune‑programming programs targeting solid tumors and other diseases. Meanwhile Liberate Bio raised $31 million seed funding to develop lipid nanoparticle (LNP) technologies for in‑vivo cell reprogramming. The moves highlight intensified investor interest in LNP‑enabled, in‑patient cell therapies that reduce ex vivo manufacturing complexity.